Article
Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.
British journal of cancer - 1 Nov 2022
Jacot William, Lusque Amélie, Vicier Cécile, Mailliez Audrey, de La Motte Rouge Thibault, Cabel Luc, Levy Christelle, Patsouris Anne, Desmoulins Isabelle, Uwer Lionel, Thery Jean-Christophe, Robain Mathieu, Caron Olivier, Tredan Olivier, Filleron Thomas, Frenel Jean-Sébastien, Delaloge Suzette
Abstract excerpt
BACKGROUND: The efficacy and added benefit of platinum-based chemotherapy (PtCT) for metastatic breast cancer (MBC) remain unclear in patients with and without germline BRCA1 or BRCA2 mutations (gBRCA1/2m and gBRCA1/2wt, respectively). METHODS: We selected from the French national real-world multicentre ESME cohort (2008-2016) all patients with HER2-negative MBC with known gBRCA1/2 status at first-line...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.